C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
about
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisGenetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer.Molecular and genetic aspects of lung cancer.Lung cancer. 9: Molecular biology of lung cancer: clinical implications.Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.Clinical impact of novel treatment strategies.The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literaturePrediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissueLack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.Therapeutic targeting of receptor tyrosine kinases in lung cancer.The role of transforming growth factor alpha production and ErbB-2 overexpression in induction of tumorigenicity of lung epithelial cellsSoluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancerMUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patientsMolecular predictors of prognosis in lung cancer.Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis.KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.Primary adenocarcinoma of the lung--histological subtypes and outcome after surgery, using the IASLC/ATS/ERS classification of lung adenocarcinoma.New prognostic factors in resectable non-small cell lung cancer.Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control studyAbsence of ras gene mutations in early gastric carcinomas.Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation.c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.
P2860
Q24650902-C52B4664-ACE0-4C12-9735-557CD6518B73Q33588251-BAB2F865-5CDB-4DAD-AF7D-E6476CAF007DQ33891465-ABEEF4A3-A2BE-47F3-80D0-54893EB44914Q33972805-45D4411F-770F-4CFF-ADC6-3E5F9956083AQ34325219-5563844D-2138-48E0-829F-C6A4A43A4B17Q34936052-F5A4986D-4796-4D64-B1E6-1FD64A8B9567Q35216052-E484879C-812F-44D6-BF2C-9BA1ACD74B5EQ36116240-B814990E-32B8-4F81-BF0D-2D560902C0ABQ36135626-74CEFFA8-7D72-45C3-87EE-27295B61849CQ36158717-E87796A5-58F4-4D57-AE03-2C5B7BE69CF0Q36292265-65933477-F804-410D-984F-941D45F41860Q36335248-904CBB78-D883-4676-B2F4-DA89D76C84EBQ36420159-8214BD6B-1360-4372-9845-783142857436Q36641208-184E0518-6B04-4AC2-A436-E2FDCBB5BF38Q36642239-60B3D3DB-1C48-4D70-B3BE-2C352A659EA2Q37227208-A4BAC748-577B-429B-983D-44A3C7923728Q37913090-AB81AB98-7154-43FF-AFD7-1DDDC0B9EAB0Q38331804-2F0A1B94-C06B-49F2-AA05-E745F051A17AQ38669282-A912B40E-2F65-442D-A128-92A0BFBB396EQ38997358-CBC02B80-C8CC-43E6-AA94-E1A0A60F3FBEQ39729571-BA149DDE-F1B4-4865-B937-D4421BA3814CQ40864750-0141E941-F3CB-4F31-A9EE-F0EBEA70DA68Q41023437-5114C4D1-1904-46CB-B33F-9A43FED1E6BBQ42106918-C90DFB19-0C10-4F94-AA50-8DB825030EE2Q43173320-B03B25CE-E01D-4845-980F-E1397922F7CEQ44120928-259F7355-6340-49DC-8EE1-E0F60BE943F1Q52122642-FAC5FA7F-7E31-4455-9C90-B0768C0544CE
P2860
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
description
1994 nî lūn-bûn
@nan
1994 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@ast
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@en
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@nl
type
label
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@ast
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@en
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@nl
prefLabel
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@ast
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@en
C-erbB-2 expression and codon ...... ith pulmonary adenocarcinomas.
@nl
P2093
P2860
P356
P1476
C-erbB-2 expression and codon ...... with pulmonary adenocarcinomas
@en
P2093
Robinson RA
Rodenhuis S
Schwartz DA
P2860
P304
P356
10.1172/JCI117001
P407
P577
1994-02-01T00:00:00Z